Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Sartorius AG
  6. News
  7. Summary
    SRT3   DE0007165631

SARTORIUS AG

(SRT3)
  Report
Delayed Xetra  -  11:35 2022-09-30 am EDT
357.10 EUR   +2.73%
09/26SARTORIUS VORZUEGE : UBS gives a Buy rating
MD
08/08Sartorius : to acquire Albumedix, strengthening its portfolio of innovat...
PU
08/08Sartorius : Stedim Biotech to acquire Albumedix, strengthening its portf...
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sartorius : Stedim Biotech to acquire Albumedix, strengthening its portf...

08/08/2022 | 12:45pm EDT

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The business, founded in 1984, has more than 100 employees and is expected to generate revenue of approximately £33 million in 2022 with a significant double-digit EBITDA margin. The agreed purchase price amounts to approximately £415 million. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.

"Albumedix will be an important addition to Sartorius Stedim Biotech's advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials. This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones," said René Fáber, member of the Board of Directors and Deputy CEO of Sartorius Stedim Biotech.

"We are delighted to be joining forces with Sartorius Stedim Biotech and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers. We have been highly impressed with Sartorius Stedim Biotech's knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius Stedim Biotech will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We remain focused on our promise of empowering excellence in the life science industry," said Jonas S. Møller, CEO of Albumedix.

The existing 72,000-square-foot Albumedix site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials in Sartorius Stedim Biotech.

Milbank LLP provided legal counsel to Sartorius Stedim Biotech in this transaction. William Blair acted as financial advisor to Albumedix, and Eversheds Sutherland provided legal counsel.

This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. This is a translation of the original French-language press release. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. The original French press release is the legally binding version.

Disclaimer

Sartorius AG published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 16:44:02 UTC.


© Publicnow 2022
All news about SARTORIUS AG
09/26SARTORIUS VORZUEGE : UBS gives a Buy rating
MD
08/08Sartorius : to acquire Albumedix, strengthening its portfolio of innovat...
PU
08/08Sartorius : Stedim Biotech to acquire Albumedix, strengthening its portf...
PU
07/21Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022
CI
07/21Sartorius Aktiengesellschaft Reports Earnings Results for the Second Quarter and Six Mo..
CI
05/19Sartorius Announces Further Growing its Global Production Capacity with Expansion of it..
CI
04/21Sartorius Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March..
CI
03/25Sartorius Aktiengesellschaft Passes the Resolution to Pay Dividends for Ordinary Share ..
CI
03/25Sartorius Aktiengesellschaft Announces Executive Changes
CI
02/17Sartorius Aktiengesellschaft Reports Earnings Results for the Full Year Ended December ..
CI
More news
Analyst Recommendations on SARTORIUS AG
More recommendations
Financials
Sales 2022 4 162 M 4 081 M 4 081 M
Net income 2022 629 M 616 M 616 M
Net Debt 2022 1 470 M 1 441 M 1 441 M
P/E ratio 2022 40,8x
Yield 2022 0,42%
Capitalization 22 785 M 22 343 M 22 343 M
EV / Sales 2022 5,83x
EV / Sales 2023 5,14x
Nbr of Employees 15 795
Free-Float 33,3%
Chart SARTORIUS AG
Duration : Period :
Sartorius AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 357,10 €
Average target price 480,90 €
Spread / Average Target 34,7%
EPS Revisions
Managers and Directors
Joachim Kreuzburg Chief Executive Officer
Rainer Lehmann Chief Financial Officer
Lothar Kappich Chairman-Supervisory Board
Oscar-Werner Reif Head-Research & Development
Volker Niebel Head-Production, Procurement & Business Operations
Sector and Competitors